DelveInsight’s, “Metastatic-Liver-Cancer Pipeline Insight 2024” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Metastatic-Liver-Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Metastatic Liver Cancer Pipeline Report

• DelveInsight’s Metastatic Liver Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Metastatic Liver Cancer treatment.
• The leading Metastatic Liver Cancer Companies such as Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.
• Promising Metastatic Liver Cancer Therapies such as ThermoDox® (LTLD), NV1020, Combretastatin A1 Diphosphate (OXi4503), Talaporfin sodium (LS11), CRS-100, EndoTAG®-1, AV-299, RO7119929, Tocilizumab, and others.
• May 2024:- Alpha Tau Medical Ltd- A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Liver Metastases. This study is a Prospective, Open label, one arm, single center study to evaluate the feasibility and safety of Diffusing Alpha Radiation Emitters for the treatment of Liver Metastases.
• May 2024:- Eureka Therapeutics Inc.- An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-3). The trial is suitable for adult subjects (≥ 18 years of age) diagnosed with GPC3-positive HCC, who have failed or not tolerated at least two (2) different anti-HCC systemic agents.

 

Explore our comprehensive Metastatic Liver Cancer Pipeline Report to stay informed about the latest advancements. Download copy now @ Metastatic Liver Cancer Pipeline Outlook

 

Metastatic Liver Cancer Overview

The liver is a common site for metastases from many cancer types. Cancers that spread to the liver most often are colorectal cancer as well as with breast, esophageal, stomach, pancreatic, lung, kidney and melanoma skin cancers. Cancers spread to the liver because the liver filters most of the blood from the rest of the body, and when cancer cells break away from a primary cancer, they often enter and travel through the bloodstream. Sometimes the discovery of metastatic liver cancer is the first indication that a person has cancer. Often, the first symptoms are vague. They include weight loss, poor appetite, and sometimes fever.

 

Metastatic-Liver-Cancer Emerging Drugs

 

• exoASO STAT6: Codiak BioSciences

exoASO™-STAT6 is an exosome therapeutic candidate engineered using our engEx™ Platform to overexpress Codiak’s novel protein scaffold, PTGFRN, to selectively target uptake in M2 polarized tumor-associated macrophages. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.

 

• STP 705: Sirnaomics

STP705, is a dual TGF-ß1/COX-2 inhibitor. TGF-ß1 and COX-2 are well-validated gatekeeper targets for oncology and fibrosis disease drug development. STP705 leverages our locally administered PNP formulation for direct administration to diseased tissue. STP705 has received U.S. orphan drug designation for the treatment of certain hepatocellular carcinomas and liver fibrosis, including: primary sclerosing cholangitis (PSC), cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.

 

• ONCR 177: Oncorus

ONCR-177, our lead product candidate, is an intratumorally administered Herpes Simplex Virus (HSV) viral immunotherapy for the treatment of multiple solid tumor cancers. ONCR-177 fights tumors through multiple mechanisms, including inherent oncolytic activity, immune stimulation elicited by viral infection and the expression of five transgenes (IL-12, CCL4, FLT3LG, anti-PD-1 and anti-CTLA-4). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.

 

Dive into our Metastatic Liver Cancer Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Metastatic Liver Cancer Treatment Therapies

 

Metastatic Liver Cancer Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for Metastatic-Liver-Cancer. The companies which have their Metastatic-Liver-Cancer drug candidates in the most advanced stage, i.e. phase I include, Oncorus.

 

DelveInsight’s Metastatic Liver Cancer Pipeline Report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Download the Metastatic Liver Cancer Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Metastatic Liver Cancer Clinical Trials Assessment

 

Metastatic-Liver-Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Metastatic Liver Cancer Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Dive into our detailed Metastatic Liver Cancer Pipeline Report to discover ground breaking advancements shaping the future of cancer treatment @ Metastatic Liver Cancer Products, Companies, and Unmet Needs

 

Scope of the Metastatic Liver Cancer Pipeline Report

• Coverage- Global
• Metastatic Liver Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Liver Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Metastatic Liver Cancer Companies- Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.
• Metastatic Liver Cancer Therapies- ThermoDox® (LTLD), NV1020, Combretastatin A1 Diphosphate (OXi4503), Talaporfin sodium (LS11), CRS-100, EndoTAG®-1, AV-299, RO7119929, Tocilizumab, and others.

 

Gain valuable insights into emerging therapies and innovations with our Metastatic Liver Cancer Pipeline Report @ Metastatic Liver Cancer Market Drivers and Barriers, Future Perspectives and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Metastatic-Liver-Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic-Liver-Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name :Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name :Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ONCR 177: Oncorus
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name :Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic-Liver-Cancer Key Companies
21. Metastatic-Liver-Cancer Key Products
22. Metastatic-Liver-Cancer- Unmet Needs
23. Metastatic-Liver-Cancer- Market Drivers and Barriers
24. Metastatic-Liver-Cancer- Future Perspectives and Conclusion
25. Metastatic-Liver-Cancer Analyst Views
26. Metastatic-Liver-Cancer Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/